1. Platinum Sensitivity in IDH1/2 Mutated Intrahepatic Cholangiocarcinoma: Not All "BRCAness" Is Created Equal.
- Author
-
Doroshow, Deborah Blythe, Wei, Wei, Mehrotra, Meenakshi, Sia, Daniella, Eder, Joseph Paul, Bindra, Ranjit, Houldsworth, Jane, LoRusso, Patricia, and Walther, Zenta
- Subjects
RESEARCH ,GENETIC mutation ,CHOLANGIOCARCINOMA ,CANCER chemotherapy ,BRCA genes ,ACQUISITION of data ,RETROSPECTIVE studies ,PLATINUM ,TREATMENT effectiveness ,CANCER patients ,COMPARATIVE studies ,MEDICAL records ,DESCRIPTIVE statistics ,RESEARCH funding ,DRUG allergy ,HEPATOCELLULAR carcinoma ,EVALUATION - Abstract
Preclinical data suggest that IDH1/2 mutations result in defective homologous recombination repair (HRR). We hypothesized that patients with IDH1/2mt intrahepatic cholangiocarcinoma (IHCC) would benefit more from 1 L platinum chemotherapy than patients with wildtype (WT) tumors. We performed a multicenter retrospective study of 81 patients with unresectable IHCC treated with 1 L platinum with a primary endpoint of clinical benefit rate (CBR). Patients with IDH1/2mt tumors had a similar CBR and objective response rate compared to those with IDH WT disease (59 versus 54%; p = 0.803), suggesting that a relationship between platinum sensitivity and HRR gene defects may be specific to tumor context. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF